Nothing Special   »   [go: up one dir, main page]

MX2018014869A - Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal. - Google Patents

Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.

Info

Publication number
MX2018014869A
MX2018014869A MX2018014869A MX2018014869A MX2018014869A MX 2018014869 A MX2018014869 A MX 2018014869A MX 2018014869 A MX2018014869 A MX 2018014869A MX 2018014869 A MX2018014869 A MX 2018014869A MX 2018014869 A MX2018014869 A MX 2018014869A
Authority
MX
Mexico
Prior art keywords
nintedanib
compositions
methods
ocular diseases
treating ocular
Prior art date
Application number
MX2018014869A
Other languages
English (en)
Inventor
Yang Rong
Ni Jinsong
Original Assignee
Cloudbreak Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cloudbreak Therapeutics Llc filed Critical Cloudbreak Therapeutics Llc
Publication of MX2018014869A publication Critical patent/MX2018014869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan composiciones y métodos de uso de nintedanib para tratar indicaciones con una neovascularización anormal en la parte frontal del ojo.
MX2018014869A 2016-06-02 2017-05-26 Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal. MX2018014869A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344870P 2016-06-02 2016-06-02
US201662344878P 2016-06-02 2016-06-02
PCT/US2017/034795 WO2017210132A1 (en) 2016-06-02 2017-05-26 Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Publications (1)

Publication Number Publication Date
MX2018014869A true MX2018014869A (es) 2019-09-13

Family

ID=60477780

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018014869A MX2018014869A (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2018014868A MX2018014868A (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2024007658A MX2024007658A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2022000754A MX2022000754A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2018014868A MX2018014868A (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2024007658A MX2024007658A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2022000754A MX2022000754A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.

Country Status (10)

Country Link
US (5) US11246864B2 (es)
EP (3) EP3463225A4 (es)
JP (4) JP7079243B2 (es)
KR (6) KR20240052865A (es)
CN (2) CN109475506A (es)
AU (5) AU2017274195B2 (es)
BR (2) BR112018074450A2 (es)
CA (2) CA3026118A1 (es)
MX (4) MX2018014869A (es)
WO (2) WO2017210130A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
JP7079243B2 (ja) 2016-06-02 2022-06-01 エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
WO2020036993A1 (en) * 2018-08-15 2020-02-20 Aiviva Biopharma, Inc. Multi-kinase inhibitors of vegf and tgf beta and uses thereof
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
GB201714392D0 (en) 2017-09-07 2017-10-25 Marsteller Laurence Methods and devices for treating glaucoma
WO2021142298A1 (en) * 2020-01-08 2021-07-15 Radiance Therapeutics, Inc. Methods, systems, and compositions for maintaining functioning drainage blebs
CA3099789A1 (en) * 2018-05-25 2019-11-28 Cloudbreak Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
CA3110287A1 (en) 2018-08-28 2020-03-05 Cloudbreak Therapeutics, Llc Emulsion formulations of multikinase inhibitors
JP2022502160A (ja) 2018-09-28 2022-01-11 ラディアンス セラピューティクス、インコーポレイテッド 低侵襲マイクロ強膜切開術に関連した、機能しているドレナージ小疱を維持するための方法、システム、及び組成物
CN113556994A (zh) 2018-11-29 2021-10-26 光辉疗法公司 应用β辐射的眼科近距离放射治疗系统和装置
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
CN110787127A (zh) * 2019-12-11 2020-02-14 龚雁 眼用温敏凝胶及其制备方法
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
CN116251186A (zh) * 2021-12-09 2023-06-13 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035668A1 (fr) 1997-02-14 1998-08-20 Kissei Pharmaceutical Co., Ltd. Medicaments entravant l'evolution du pterygion et sa recurrence postoperatoire
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006020979A2 (en) 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US9993558B2 (en) * 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
WO2007038453A2 (en) 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
RU2351298C1 (ru) 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ профилактики рецидива птеригиума
TW201201808A (en) 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
CN102018686B (zh) 2010-12-16 2012-12-05 浙江大学医学院附属邵逸夫医院 含有丝裂霉素的膜剂及其制备方法
WO2012095521A1 (en) * 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
US20140296301A1 (en) 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
CN103212075B (zh) * 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
WO2013126799A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
CA2877678A1 (en) 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing cediranib
EP2858628A1 (en) 2012-06-25 2015-04-15 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sunitinib
CA2877710A1 (en) 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
CN104379133A (zh) 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有阿昔替尼的局部眼科药物组合物
WO2014059233A1 (en) * 2012-10-11 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Ocular filtration devices, systems and methods
KR20150083117A (ko) 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN104955471A (zh) 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US20160038760A1 (en) 2013-03-14 2016-02-11 Massachusetts Eye And Ear Infirmary Conjunctival diseases
KR102406619B1 (ko) 2013-05-03 2022-06-07 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
AU2015305269B2 (en) 2014-08-22 2021-12-23 Auckland Uniservices Limited Channel modulators
CN104448300B (zh) 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
WO2016123151A1 (en) 2015-01-26 2016-08-04 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
MX370113B (es) 2015-06-09 2019-12-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2.
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
CA2993182A1 (en) 2015-07-22 2017-01-26 Incept, Llc Coated punctal plug
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7081818B2 (ja) 2016-02-04 2022-06-07 エーディーエス・セラピューティクス・エルエルシー 疾患治療のための抗体－薬剤相乗作用技術
JP7079243B2 (ja) 2016-06-02 2022-06-01 エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
BR112021026662A2 (pt) 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho

Also Published As

Publication number Publication date
US10688092B2 (en) 2020-06-23
KR20240049636A (ko) 2024-04-16
WO2017210130A1 (en) 2017-12-07
AU2022204216B2 (en) 2024-10-17
MX2022000754A (es) 2022-02-14
JP2022116191A (ja) 2022-08-09
CN109561985A (zh) 2019-04-02
MX2024007658A (es) 2024-07-04
US11246864B2 (en) 2022-02-15
EP3463225A1 (en) 2019-04-10
EP3463315A1 (en) 2019-04-10
AU2022202629A1 (en) 2022-05-19
BR112018074454A2 (pt) 2019-03-19
WO2017210132A1 (en) 2017-12-07
KR20230023812A (ko) 2023-02-17
EP4248971A2 (en) 2023-09-27
AU2017274195B2 (en) 2022-04-07
KR20190040935A (ko) 2019-04-19
KR20240052865A (ko) 2024-04-23
AU2022204216A1 (en) 2022-07-14
JP2024083587A (ja) 2024-06-21
AU2017274197B2 (en) 2022-02-10
AU2024219639A1 (en) 2024-10-03
CA3025325A1 (en) 2017-12-07
EP4248971A3 (en) 2024-02-14
EP3463315B1 (en) 2023-06-14
US20190290643A1 (en) 2019-09-26
AU2017274195A1 (en) 2018-12-13
US20220125783A1 (en) 2022-04-28
EP3463315A4 (en) 2020-01-15
US20200323844A1 (en) 2020-10-15
JP2019517578A (ja) 2019-06-24
KR20190032300A (ko) 2019-03-27
JP7082115B2 (ja) 2022-06-07
KR102496234B1 (ko) 2023-02-06
MX2018014868A (es) 2019-09-13
US20190015409A1 (en) 2019-01-17
BR112018074450A2 (pt) 2019-03-19
EP3463225A4 (en) 2020-03-11
JP7475395B2 (ja) 2024-04-26
US11911379B2 (en) 2024-02-27
AU2022202629B2 (en) 2024-06-13
EP3463315C0 (en) 2023-06-14
KR102657707B1 (ko) 2024-04-15
US10335408B2 (en) 2019-07-02
JP7079243B2 (ja) 2022-06-01
KR102408596B1 (ko) 2022-06-13
CN109475506A (zh) 2019-03-15
US20240238279A1 (en) 2024-07-18
JP2019518790A (ja) 2019-07-04
KR20220080222A (ko) 2022-06-14
CN109561985B (zh) 2022-03-04
CA3026118A1 (en) 2017-12-07
AU2017274197A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EP3261440A4 (en) Methods and compositions for treating genetic eye diseases
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MY186271A (en) Ophthalmic compositions and methods of use therefor
PT3472317T (pt) Composições e métodos para reduzir a neovascularização ocular
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
IL282447A (en) Methods and preparations for healing eye cell
MX2018009426A (es) Vector aav-idua para el tratamiento de ceguera asociada con mucopolisacaridosis i (mps i).
ZA201807438B (en) Methods of treating ocular conditions
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
EP3481411A4 (en) TREATING GLAUCOMA AND OTHER EYE DISEASES
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
ZA201703467B (en) Methods of treating ocular conditions
EP3634438A4 (en) COMPOSITIONS FOR THE TREATMENT OF RETINAL DISEASES AND THEIR PRODUCTION AND USE METHODS
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
EP3519050A4 (en) COMPOSITIONS AND METHODS FOR TREATING OPHTHALMOLOGICAL DISORDERS
AU201612415S (en) Front frame for swimming goggles